• From CA2 Nets to Translational Assays

  2026-09-16

  The loss of hippocampal CA2 perineuronal nets offers a mechanistic explanation for social-memory impairment in Alzheimer’s disease models. This thought-leadership article translates that insight into an assay-development strategy, while positioning 8-DY547-cGMP as a carefully qualified, orthogonal reagent for exploring cyclic-GMP-linked biology without overstating what the current evidence proves.

• Epigenetic Immune Signatures in Melanoma

  2026-09-15

  Anichini and colleagues compared distinct epigenetic drug classes in melanoma and found that guadecitabine most consistently induced tumor-cell immune programs linked to innate sensing and interferon signaling. The study integrates cell-line profiling, protein validation, patient biopsies, xenograft analysis, and TCGA prognostics to identify epigenetic immune priming as a rational strategy for improving checkpoint-blockade responses.

• Dorsomorphin (Compound C) in AMPK and BMP Assays

  2026-09-15

  Dorsomorphin (Compound C) enables reversible, cell-permeable interrogation of AMPK and BMP-SMAD signaling in metabolic, autophagy, differentiation, and bone-formation models. This workflow-focused guide shows how to separate pathway effects, translate a recent Wnt–glycolysis study into assay design, and troubleshoot solubility, timing, toxicity, and interpretation problems.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-09-14

  The reference study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that links lipid-associated metabolic dysfunction to impaired MHC-I antigen presentation in MASH-HCC. Its mouse-model experiments suggest that reducing intracellular bile acid retention can restore tumor antigenicity and improve anti-PD-1 responses, while also providing a framework for mechanistic cytokine and immune-cell assays.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide

  2026-09-14

  Explore how the FITC Goat Anti-Rabbit IgG (H+L) Antibody supports pathway-resolved fluorescence assays in DON and lycopene intestinal toxicity research. This guide connects ERK–NLRP3 biology with practical controls, modality selection, and reproducible signal interpretation.

• Heart–Insula Axis Dysregulation in PTSD Mice

  2026-09-13

  The reference study identifies a vagus-dependent heart–insula pathway in which sympathetic cardiac overactivation drives insular cortex hyperactivity and PTSD-like behaviors in mice. By combining isoproterenol modeling, cervical vagotomy, electrophysiology, immunofluorescence, and propranolol rescue, it provides a mechanistic framework for studying neurocardiac signaling rather than treating cardiac and behavioral phenotypes as independent outcomes.

• Forsythoside E PKM2 Workflow Guide

  2026-09-12

  Forsythoside E enables a mechanism-led workflow linking PKM2 tetramerization with macrophage metabolic remodeling, M2 polarization, and reduced inflammatory signaling. This guide translates the reported binding, cell-based, and mouse data into practical assay design and troubleshooting strategies for sepsis-induced liver injury research.

• Subtype-Specific SST Plasticity During Sensory Learning

  2026-09-11

  Mosso et al. identify learning-associated plasticity in a molecularly defined subset of layer 2/3 somatostatin interneurons, rather than a uniform change across the SST population. Their longitudinal calcium-imaging and label-free classification strategy provides a framework for relating interneuron subtype, sensory response, and learning history in cortical circuits.

• CB-839 (Telaglenastat) in Cancer Metabolism

  2026-09-11

  CB-839 (Telaglenastat) enables a controlled, reversible way to test GLS1 dependence, glutamate depletion, and stress responses in cancer models. This guide converts the PRMT5–splicing findings in MYCN-amplified neuroblastoma into practical assay designs for cancer metabolism research and preclinical cancer drug evaluation.

• Universal nPEC Assay for Dual-Loaded Liposomes

  2026-09-10

  Tong Yuan and colleagues compared six separation strategies for measuring the encapsulation efficiency of lipophilic and hydrophilic drugs co-loaded into liposomes. Their validated nanoparticle exclusion chromatography method enabled simultaneous online quantification across three model drug pairs and offered a less laborious alternative to methods with narrower formulation compatibility.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-10

  A 2025 Cancer Biology & Medicine study identifies MDM1 as a functional determinant of colorectal cancer chemoradiotherapy response, rather than only a correlative biomarker. The work links MDM1 overexpression to reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, and enhanced apoptosis, providing a mechanistic basis for treatment-response prediction and resistance studies.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-09

  Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated CYP and transporter activities, creating a more human-relevant platform for oral drug absorption and metabolism studies.

• Baicalein Workflows for Cancer and Inflammation

  2026-09-09

  Build reproducible Baicalein assays around 12-LOX inhibition, apoptosis, inflammatory signaling, and cancer-cell response rather than relying on a single endpoint. This practical workflow also translates a recent neurotoxicity study into a paired neuronal–tumor assay strategy while clearly separating evidence from hypothesis.

• GLI2, WNT, and Prostaglandin Signaling in ICB Resistance

  2026-09-08

  The reference study identifies GLI2 as a mechanistic coordinator of tumor immune evasion during mesenchymal transformation, linking WNT ligand production and prostaglandin signaling to myeloid suppression and impaired antitumor lymphocyte function. Its intervention-based design suggests that GLI2-associated resistance may be addressed through rational combinations involving immune checkpoint blockade, WNT signaling, or prostaglandin receptors, while the clinical signature analysis provides a translational framework for patient stratification.

• Anti-Epileptic Drugs and Human PON1 Inhibition

  2026-09-08

  The reference study quantitatively compared how five antiepileptic drugs inhibit purified human serum paraoxonase-1 (hPON1), identifying noncompetitive inhibition for every compound tested. Phenytoin showed weaker inhibition than gabapentin, valproic acid, and primidone but stronger inhibition than levetiracetam, providing a biochemical perspective on drug–enzyme interactions that complements sodium channel and electrophysiology research.

8563 records 1/571 page Next 12345 下5页 Last page